{"changeSha256":"403caf2db06b9fb11080a4230c1a444ec8462e141f7fbcf1b81b30d9b07ed3c2","changedAt":"2026-11-16","changedFields":[{"after":"Two very small early human studies, one placebo-controlled in 10 men, report skin darkening, erections and nausea. FDA cites case reports of melanoma, brain swelling, stimulant-like toxicity and priapism. No FDA approval is reported, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.","before":"FDA cites published case reports of melanoma, brain swelling, stimulant-like toxicity and priapism in people who used Melanotan II. No FDA approval is reported in the cited sources, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.","field":"Evidence note"},{"after":"fda-melanotan-ii-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026, fda-pcac-503a-meeting-2027, journal-pmid-8637402, journal-pmid-11018622","before":"fda-melanotan-ii-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026","field":"Cited source records"},{"after":"name: fda-melanotan-ii-identity, fda-bulk-peptide-risks; aliases: fda-melanotan-ii-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-melanotan-ii-identity, fda-bulk-peptide-risks; evidenceNote: journal-pmid-8637402, journal-pmid-11018622, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"name: fda-melanotan-ii-identity, fda-bulk-peptide-risks; aliases: fda-melanotan-ii-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-melanotan-ii-identity, fda-bulk-peptide-risks; evidenceNote: fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/melanotan-ii/versions/2/","version":2},"id":"profile:melanotan-ii:v2","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We added two early human studies of Melanotan II and FDA’s advisory committee page listing it for a meeting before the end of February 2027.","peptideSlugs":["melanotan-ii"],"previousChangeEvent":null,"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/melanotan-ii/versions/1/","version":1},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"journal-pmid-8637402","name":"Life Sciences","sourceClass":"A","title":"Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study (1996) · PMID 8637402","url":"https://doi.org/10.1016/0024-3205(96)00160-9","verifiedAt":"2026-11-16"},{"id":"journal-pmid-11018622","name":"Urology","sourceClass":"A","title":"Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction (2000) · PMID 11018622","url":"https://doi.org/10.1016/s0090-4295(00)00680-4","verifiedAt":"2026-11-16"},{"id":"fda-pcac-503a-meeting-2027","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027) · content current as of April 15, 2026","url":"https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee","verifiedAt":"2026-11-16"}],"subject":{"slug":"melanotan-ii","type":"profile"}}
